A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Key Inclusion Criteria: * Recipients of either first- or second-line chemotherapy for advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer or myeloma, selected lymphomas, or cancer of unknown origin * Able to begin study medication ≤6 weeks of starting either first- or second-line chemotherapy. * Expected course of chemotherapy must have been ≥ 90 days after the start of chemotherapy * Per Protocol Amendment 5, patients receiving bevacizumab were eligible to participate, provided that bevacizumab was used for indications approved by local country law Key Exclusion Criteria: * Women who are pregnant, breastfeeding * History of deep vein thrombosis or pulmonary embolism * Active bleeding or at high risk of bleeding * Metastatic brain cancer * Familial bleeding diathesis * Serious hemorrhage requiring hospitalization, transfusion, or surgical intervention within 4 weeks of study entry * Expected survival \<6 months or an Eastern Cooperative Oncology Group performance status ≥3. * Candidates for bone marrow transplantation within the 12-week treatment period or 30-day follow-up period * Uncontrolled hypertension (systolic blood pressure \>200 mm Hg and/or diastolic blood pressure \>110 mm Hg * Coagulopathy (international normalized ratio \>1.5 or platelet count \<100\*10\^9/L) if not yet receiving chemotherapy or \<50\*10\^9/L if receiving chemotherapy). Platelet count must have been \>100\*10\^9/L before starting study medication * One or more of the following: alanine aminotransferase \>3 times the upper limit of normal (ULN), total bilirubin \>2\*ULN, or calculated creatinine clearance \<30 mL/min.